EHA 2016 | What does a physician need to consider when treating relapsed or refractory myeloma?
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discusses treatment options for relapsed and refractory multiple myeloma (MM) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Due to it is current high prevalence in the research field, the physician’s role is becoming harder as there is a wider choice of therapies. When choosing these therapies practitioners need to consider age, co-morbidities, prior history, bone-marrow reserves, organ dysfunction, as well as disease features and manifestations. When putting these components together, management and sequence of treatments becomes complex. However, Prof Mohty is confident that on a case by case basis it is possible to identify the optimal treatment for a patient.
Get great new content delivered to your inboxSign up